anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PCT No. PCT/SE94/00422 Sec. 371 Date Oct. 30, 1995 Sec. 102(e) Date Oct. 30, 1995 PCT Filed May 6, 1994 PCT Pub. No. WO94/26287 PCT Pub. Date Nov. 24, 1994Virus inactivating chemicals and/or detergents in an aqueous composition containing a water-soluble plasma protein are reduced by selecting a suitable combination of temperature and concentration above 0.5M of salt with a high salting out effect according to the Hofmeister series, thereby forming vesicles containing the virus inactivating chemical and/or detergent. These vesicles are removed from the aqueous phase, e.g. by phase separation or filtration, and the protein thereafter isolated from the aqueous phase. The water-soluble plasma protein can be e.g. antithrombin III, transferrin or albumin. When the aqueous phase comprises e.g. a salt of citrate or sulphate in a concentration above 1M at room temperature, the reduction of virus inactivating chemical or detergent can be as high as 2000 times or more, giving a final concentration below 5 ppm.
FIELD: medicine. SUBSTANCE: agent consists of the spirituous extract of sea-buckthorn fruits, licorice root and rhizome, aralia root, rose fruits, Bergenia pacifica leaves, medicinal ginger fruits and medicinal dandelion root. Agent is prepared by extraction of indicated plant raw with ethanol at the ratio raw: extractant = 1:(10-15) at 50-70 C, triple by 2 h. Prepared extracts were combined and filtered. Extractive matter content is 10%. EFFECT: increased radioprotective activity of proposed agent as compared with that of medicinal dandelion extract. 3 cl
BACKGROUND: The medial femoral trochlea flap has been used to resurface scaphoids with recalcitrant proximal pole fractures or avascular necrosis, providing vascularized osteochondral tissue with similar morphological characteristics. This article aims to review the contemporary literature on its use for scaphoid reconstruction.
METHODS: A systematic review of Embase, PubMed, Cochrane Central Register of Controlled Trials, and MEDLINE assessed the use of medial femoral trochlea flaps in scaphoids.
RESULTS: Eight studies were included, with 76 patients at a mean age of 26 years. Forty-three patients underwent clinical review, and 10 patients underwent radiographic evaluation, at a mean 23.3 months of follow-up. Flaps were generally performed for proximal pole fractures, avascular necrosis, nonunion, or failure of prior fixation; 94.4% of the flaps united. No marked change in sagittal plane motion was noted; reductions were seen in axial and coronal plane motion. The Disabilities of the Arm, Shoulder, and Hand scores improved from a mean of 25.2 to 11.5. Radiographic markers also improved. A total of 12.3% of patients had unplanned return to theater. Three patients required early revision for vascular thrombosis, and 1 patient suffered a volar carpal dislocation. Three patients underwent salvage procedures for ongoing pain.
CONCLUSIONS: Although technically demanding, promising early-term to medium-term results are noted with the use of medial femoral trochlea flaps in the scaphoid.
CON session will perform at controlled heated water-base (30 e 32 ºC). Subject will be seated in a chair and submerged at the xiphoid process level for 30 min.
This will be a 2 arm prospective clinical trial. Men with clinical suspicion for PCa but no prior prostate biopsy will be enrolled from the University of Illinois (UI) Health Urology clinics. All eligible men will be screened and enrolled by the clinical research coordinator. Enrolled men will undergo detection protocol MRI at the UIC Advanced Imaging Center (AIC) prior to diagnostic biopsy. The MRI will be processed by the study team and evaluated for areas suspicious for high grade PCa by a board certified clinical radiologist. Subjects with MRI with no suspicious areas for high grade PCa will undergo standard of care (SOC) core transrectal ultrasound (TRUS) biopsy. Subject with MRI suspicious for high grade PCa will have 2-4 biopsies guided toward each suspicious lesion using MRI/TRUS fusion biopsies (maximum of 12 cores). All biopsies will undergo SOC histologic processing and interpretation in pathology. Biopsy results will be communicated to the patients by the Urologist performing the biopsy and all additional management will be SOC. This visit will signify the end of the study
PURPOSE: To provide a product based on a combination of an organochromium compd. with two kinds of vitamins having antioxidant effect such as vitamin E and vitamin C as a dietary for preventing diseases of a cardiac vessel. CONSTITUTION: A combination of an organochromium compd. with two kinds of vitamins having antioxidant effect such as vitamin E and vitamin C is used so as to prevent diseases of a cardiac vessel by regulating the metabolism of carbohydrate and the peroxidation of lipid. For example, a product contg. 57.5% lactose, 21.4% organochromium compd., 14.25% vitamin C, 5.7% tocopherol acetate, 1.0% precipitated silica and an allowable dye is fed in the form of an ordinary medication unit such as capsules, tablets or pills for oral administration.
Regular physical exercise appears to potentiate the effects of pharmacological treatment for arterial hypertension. As such, regular exercise is recommended as an adjuvant treatment in hypertensive subjects by both European and American guidelines. Crucially, however, there are no precise recommendations on the type of physical exercise and how it should be instituted. Aerobic Interval Training (AIT) is a new and novel type training that appears to be beneficial to patients suffering from various medical conditions. There is a distinct lack of evidence on how it affects arterial hypertension. The aim of this study was to evaluate the influence of a 5 month period of regular AIT on blood pressure, carotid femoral pulse wave velocity (PWV) and applanation tonometry indexes in patients previously treated pharmacologically for mild or moderate arterial hypertension.

The study group consisted of 60 hypertensive subjects (30 males, 30 females) (age 54.45 ± 8.52 years) who had previously undergone at least 2 years of combined anti-hypertensive therapy and who had well controlled hypertension, i.e. below 140/90 mmHg. Their pharmacological treatment did not change during the study period. The study group was randomly divided into 2 subgroups. In the first group (G1), AIT was undertaken for 5 months (40 professional AIT sessions performed two times per week in 50 minute sessions) and followed a specially developed program. The second control group (G2), did not attend any training sessions but received medical advice on how to maintain physical activity as outlined by JNC (Joint National Committee) hypertension guidelines. During the baseline visit and then at five months (final visit), both groups underwent testing for office BP (blood pressure), PWV and applanation tonometry indexes using the SphygmoCor® device and the Complior® device.
Escalating doses Dose escalation design with two dose levels. The low dose level involves a single intravenous infusion of γMSCs at 2x106 cells/kg. The high dose level involves a single intravenous infusion of γMSCs at 5x106 cells/kg.
Cervical cancer (CaCx) ranks as the fourth most prevalent cancer among women globally. Persistent infection of high-risk human papillomaviruses (HR-HPVs) is major etiological factor associated with CaCx. Signal Transducer and Activator of Transcription 3 (STAT3), a prominent member of the STAT family, has emerged as independent oncogenic driver. It is a target of many oncogenic viruses including HPV. How STAT3 influences HPV viral gene expression or gets affected by HPV is an area of active investigation. A better understanding of host-virus interaction will provide a prognostic and therapeutic window for CaCx control and management. In this comprehensive review, we delve into carcinogenic role of STAT3 in development of HPV-induced CaCx. With an emphasis on fascinating interplay between STAT3 and HPV genome, the review explores the diverse array of opportunities and challenges associated with this field to harness the prognostic and therapeutic potential of STAT3 in CaCx.
NCPAP provides continuous distending airway pressure during inspiration and expiration via nasal prongs; this has been shown to increase lung volume by increasing alveolar size, recruiting collapsed alveoli, and preventing atelectasis. Improved lung volumes decrease V/Q mismatch and improve the clinical course of neonates with RDS, and as such, early NCPAP use often avoids the need for intubation and mechanical ventilation. Newborns receiving bubble NCPAP will be placed on a PEEP 5cm H2O, and supplemental oxygen will be provided to maintain oxygen saturation between 88-93% (standard of care group) as is standard practice. The size of the nasal prongs used will be based on the subject's weight as per the manufacturer instructions.
GRIPonMASH is an observational study in which 10.000 high risk patients (type 2 diabetes mellitus, metabolic syndrome, obesity or arterial hypertension) in 10 different European countries will be screened for the presence of MASLD, liver fibrosis and (at-rsik) MASH using at least two non-invasive tests (FIB-4 and FibroScan). Additional published and exploratory non-invasive test will also be investigated. Blood samples and liver biopsy material will be collected. Genomic, proteomic, metabolomic, lipidomic and fluxomic studies will be applied to gain a better understanding of the pathophysiology of MASLD and to identify (bio)markers that will help to detect patients at-risk. The predictive value of FIB-4 in relation to FibroScan results and liver biopsy will be analysed. Long-term follow-up of 5 years in all participants will provide insight into the natural history of the disease.
The utility model could be applied in cases of colds and flues. The herbal composition has the following contents: stems of Herba Thymi (thyme), leaves of Folia Menthae pip. (peppermint) and roots ofRad. Liquiritae (liquorice), leaves of Fol. Salviae (garden sage) and/or roots of Rad Taraxaci (dandelion) or stems of Herba Origanum vulgare (wild marjoram), leaves of Folia Farfara (colt's foot) and stems and/or roots of Rad/ Herba Echinacea (echinacea) and/or stems of Herba Agrimoniae (agrimony) and stems and/or roots of Hb Rad. Primula (cowslip) or petals of Flores Chamomila (chamomile) and, in certain embodiments, stems of Herba Visci Albi (mistletoe). The benefits of the composition lie in its enhanced therapeutic action that the specially selected herbs provide. Their biologically active substances contained in the total extract possess anti-allergic, anti-flu, antispastic, anti-inflammatory and astringent effects.
Medical apparatus is described including a fiducial component and a position sensor. The component is recognizable as at least a part of a fiducial when appearing in image data of a patient. The component is attachable to the patient. The sensor is attachable to the component at a predetermined location and orientation on the component or is capable of being positioned adjacent the fiducial component without attachment thereto at a predetermined location and orientation. A storage medium is described containing a program which instructs the computer to recognize a predetermined shape of each of at least one portion of a position sensor as at least a part of a real-world fiducial in image data of a patient. The position sensor is adapted to provide position data. Medical apparatus which includes the position sensor and the storage medium is also described.
The invention belongs to the fields of chemical engineering and medicines, and relates to applications of diacetylbritannilactone in preparation of antitumor medicines. The invention provides the applications of diacetylbritannilactone in preparation of antitumor medicines. The invention also provides a method of inhibiting in-vitro tumor cell proliferation, namely a method of adding the diacetylbritannilactone into a culture solution of tumor cells. The diacetylbritannilactone is a natural product and can obviously inhibit tumor cell proliferation. The small molecule compound is developed as a novel antitumor medicine or an auxiliary element thereof. The diacetylbritannilactone is obvious in tumor-inhibiting effects and green, and provides a novel route and a novel manner for treating and curing tumor.
In the intervention group the first mask will be randomly chosen between the two most used in that center among those available i.e., oro-nasal, total face or hybrid mask. Thereafter, NPPV mask will be changed every 6 hours, alternating the two different interfaces. Patients wearing oro-nasal masks will receive protective dressings on nasal bridge before starting NPPV.
PCT No. PCT/JP95/02110 Sec. 371 Date Jun. 13, 1996 Sec. 102(e) Date Jun. 13, 1996 PCT Filed Oct. 13, 1995 PCT Pub. No. WO96/11715 PCT Pub. Date Apr. 25, 1996A restorative composition for hard tissue, comprising a paste (A) containing an inorganic calcium phosphate powder, a polymerizable monomer mixture and a polymerization initiator, and a paste (B) containing an inorganic calcium phosphate powder, a polymerizable monomer mixture and a polymerization accelerator, wherein the content of the inorganic calcium phosphate powder in each paste is 75-85% by weight, and each monomer mixture contains a monomer of the formula (1):    <IMAGE>  (1)  and a monomer of the formula (2):    <IMAGE>  (2)   <IMAGE>   the content of the monomer (1) accounting for 40-65% by weight of the monomer mixture as a whole. The composition can well adhere to the bone and has a sufficient water resistance. As it generates little heat upon hardening, it is less detrimental to the patient's tissues. Furthermore, the paste has an appropriate consistency, which facilitates homogeneous mixing of the paste and application of the resultant mixture to the affected part by the use of a dispensing apparatus. Thus, the restorative composition can be used not only as a bone cement but also as a filler for the defected part of the bone, a bone prosthesis or an artificial bone.
1,193,153. Coloured nitrocellulose compositiond. L'OREAL. 16 July, 1968 [3 Aug., 1967], No. 35691/67. Addition to 1,193,154. Heading C3F. A nitrocellulose-based nail varnish contains at least one coloured polymer having a backbone of carbon atoms and containing side chains linked to the backbone either directly or through methylene groups by amide linkages, which side chains comprise coloured radicals, with the provisos that, ignoring said side chains containing coloured radicals and any other side chains containing a carbonyl group linked to the polymer either directly or through methylene groups, but not ignoring the methylene groups if present, the recurring units are not all the same, and that when only one of the types of recurring unit contains a coloured radical, this unit is not of the formula In examples the coloured polymer is based on isobutyl vinyl ether/itaconic anhydride copolymer condensed with 1-(gamma-aminopropylamino) anthraquinone or methyl acrylate/ acrylic anhydride copolymer condensed with 2 - methyl - 4 - nitro - 5 - (beta - amino ethylamino) aniline. Other compounding ingredients are an aryl sulphonamide/formaldehyde resin, butyl phthalate, camphor, ethyl and butyl acetates, absolute ethanol, butanol and toluene. Pearl essence or a white pigment may optionally be added.
Patients will receive 2 cycles of 3-weekly schedule of induction chemotherapy, consisting of paclitaxel 135 mg/m2, cisplatin 75 mg/m2, and cadonilimab 10 mg/kg on day 1 prior to CRT. Then all patients will receive standard fractionation radiation therapy scheme: 50.4 Gy in 28 fractions, concurrently with 2 cycles of cadonilimab. After the completion of radiotherapy, patients will then receive 12 additional cycles of cadonilimab.
In this comparison of; lidocaine 5%, lidocaine/menthol 1.25% and placebo for patients with back pain and arthritis, subjects had to qualify by meeting various inclusion and exclusion criteria. Subjects signed an informed consent and were randomized in a double blinded fashion to one of the three arms. After randomization subjects completed a baseline questionnaire regarding how pain affects their lives. Then they began therapy with their blinded product. This same questionnaire was administered after the second day of therapy and after the final day on day 10. Responses at the day two and ten endpoints were compared to baseline to access the response of each arm.
Computer-aided diagnosis algorithms require a large volume of training data. The existing methods for simulating artificial biomedical signals are mostly based on physics driven mathematical models that require too many assumptions, making them challenging to simulate on a large scale. Alternatively, conventional deep learning-based approaches are pure data driven and hence, do not have physiological interpretation. The present disclosure provides a method that effectively combines both physiological domain knowledge and deep learning to enable simulation of realistic cardiovascular disease specific biomedical signals. An ensemble Generative Adversarial Network (GAN) including a Long Short-Term Memory GAN (LSTM-GAN) configured to generate a Heart Rate Variability (HRV) pattern associated with the cardiovascular disease condition and a Deep Convolutional GAN (DCGAN) configured to create a morphology of a representative cardiac cycle is provided. A complete waveform is simulated by combining an output from each GAN.
FIELD: medicine, pharmacy. SUBSTANCE: invention relates to the complex homeopathic agents. Medicinal agent is a two-component complex homeopathic preparation. Preparation A has Aconitum napellus, Rhus toxicodendron and Arsenicum jodatum taken at equal weight ratios, and preparation B has Phytolacca, Bryonia and Hepar sulfuris taken at equal weight ratios. Components of preparations A and B were taken at dilutions as used by homeopathic method. For disease treatment preparations A and B were given in turn: 5 granules or drops every 30 min during the first two days and 3 granules or drops after every 2 h for the following days up to recovery. EFFECT: enhanced effectiveness of treatment. 3 cl
PCT No. PCT/US93/06792 Sec. 371 Date Apr. 5, 1995 Sec. 102(e) Date Apr. 5, 1995 PCT Filed Jul. 20, 1993 PCT Pub. No. WO94/04165 PCT Pub. Date Mar. 3, 1994The present invention relates to the use of certain anionic polyamide and polyurea oligomers for inhibiting angiogenesis, and for their use in treating diseases associated with angiogenesis. These oligomers have a number average molecular weight (Mn) less than 10,000, comprise recurring units coupled by carbonyl linking moieties and have predominantly linear geometry such that regular spacing between anionic groups exists in an aqueous medium. The oligomers also have a preferably linear backbone and be be in their salt form, preferably wherein the salt is pharmaceutically acceptable.
<P>PROBLEM TO BE SOLVED: To provide a disposable rubber sponge to be used for painkilling anti-inflammation fomentation moderating pains such as hip injury and antipruritic anti-inflammation fomentation for insect bite, in which used rubber sponge can be removed from for disposal and be replaced with a new disposable sponge.  <P>SOLUTION: An existing rubber sponge 5 is attached on a rubber sponge mounting part 4 made provided on a plastic container 1, and the rubber sponge 5 is fitted with a case-shaped rubber sponge 6 for replacement. By this composition, rubber sponge 6 for replacement can be mounted on the existing rubber sponge 5 when another person uses it. Therefore, when the original user applied it, the rubber sponge 6 for replacement which another person used can be removed, and the original existing rubber sponge 5 is used, thus solving the problem of hygiene. A new rubber sponge for replacement may be mounted when the original user apply.  <P>COPYRIGHT: (C)2006,JPO&NCIPI
Standard cystoscopy with normal saline solution containing Neosporin® G.U. at a 1mL/1000mL concentration.
After providers consent to participate in this study, a screening tool will be deployed for their weekly clinics to identify patients at high risk of having undiagnosed PAD. These high risk alerts will be provided after a patient has checked in for their outpatient appointment. The alert will be sent to their treating provider once the visit is initiated in the electronic health record system (EHR). The primary outcome measure is overall rate of new PAD diagnoses. Secondary outcomes include rate of new secondary prevention measures initiated for PAD, which will include new prescriptions for antiplatelets, PAD-dosed rivaroxaban, statins, smoking cessation counseling or referrals, and/or supervised exercise therapy referrals also aggregated at a clinic and site level. For secondary analysis we will specifically evaluate patients who generated an alert and assess how patient demographics and/or clinical factors are associated with likelihood of ABI testing, rate of abnormal ABIs (i.e. true positive rate), and subsequent initiation of secondary prevention measures.

UC San Diego Health (UCSDH), VA San Diego Health Care (VASDHC), and Stanford Health Care (SHC) will be the sites for study enrollment. UCSDH - La Jolla campus, UCSDH - Hillcrest campus, and VASDHC will begin a pre-intervention observation period at the same time, and then each site will be randomized to begin screening tool intervention in a stepped wedge pattern at 13-week intervals for a total of 52 weeks. We will enroll 10 clinics per site based on power calculations for number of patients needed to screen each week and to minimize the number of alerts per clinic/ provider. After this 52 week period, the Stanford site will serve as a validation site and will undergo randomization of 10 clinical sites to three 13 week intervals for a total of 52 weeks.
The purpose of this study is to implement and evaluate the Healthy Kids+ initiative -- a community-engaged research project - through an existing after-school program in Las Cruces, NM. The Healthy Kids+ initiative will encourage daily lifestyle behaviors (5 or more servings of fruits and vegetables, 2 hours or less of recreational screen time, 1 hour of physical activity, 0 sugary drinks, 10 hours of sleep) that impact childhood obesity. This research project will integrate lessons and activities designed to help kids incorporate changes into their lives to enhance their health and wellness. Overall, it is expected that children participating in the Healthy Kids+ initiative, three times per week, will demonstrate significant changes in improving lifestyle behaviors and maintaining both cognitive and affective changes.Healthy Kids+ will be integrated into the 21st Century afterschool program to provide children at the school sites with relevant PA and health related programming throughout the year. The proposed study will include a repeated-measures research design. A power analysis revealed that for a moderate effect size (f = .25, Cohen, 1988), with five percent type I error and 80% power, three follow up time points, and within subject's correlation of 0.5, we will need to recruit at a minimum 100 total participants. However, our potential participant pool is much larger, and thus we plan on over recruiting (N = 200) to mitigate lost data from attrition rates. The Healthy Kids+ program will be implemented three times a week for 30 weeks. A midyear assessment will be conducted 15-weeks into the program. Participants will then take part in a post assessment at the completion of the 30-week program. The primary quantitative outcome measures include levels of lifestyle behaviors (PA, healthy eating habits, screen time, sleep). The outcome measures will also include self-efficacy, self-esteem, and the level of readiness to change relevant to aforementioned lifestyle behaviors.

Based on Healthy Kids+, we revised and partnered with Fred Hutchinson Cancer Center to expand this trial. For this follow up project, we will recruit 30 children total at NMSU. For this follow up project, we will use accelerometer to objectively measure physical activity and sleep, as well as validated surveys measures for dietary intake and related health outcomes.